Improving Breast Cancer Detection After Breast Conservation Therapy
Women aged 50 years or younger who underwent breast conservation therapy may benefit from breast magnetic resonance imaging (MRI) screening as an adjunct to mammography, according to a new study published in JAMA Oncology.
“After breast conservation therapy in women 50 years or younger, the addition of MRI to annual mammography screening improves detection of early-stage but biologically aggressive breast cancers at acceptable specificity [correctly identifying people who don’t have disease]. Results from this study can inform patient decision-making on screening methods after breast conservation therapy,” study authors write.
Women who are treated with breast conservation surgery and radiotherapy remain at an increased risk for second breast cancers. The study compared outcomes for combined mammography and MRI or ultrasonography screenings for new breast cancers in women who have previously undergone breast conservation surgery and radiotherapy for breast cancer initially diagnosed at 50 or younger.
The multicentre comparison study, led by Woo Kyung Moon, MD, of the Seoul National University College of Medicine in South Korea, included 754 women. Annual mammography, breast ultrasonography and breast MRI were performed for both conserved and contralateral (opposite) breasts during a three-year study period for a total of 2,065 mammograms, ultrasonography and MRI screenings.
The researchers report 17 cancers were diagnosed and 13 of the 17 cancers were stage 0 or stage 1. The addition of MRI screening to mammography detected 3.8 additional cancers per 1,000 women over mammography alone and the addition of ultrasonography to mammography detected 2.4 additional cancers, according to results of the study.
Limitations of the study include there was no control group for comparison of women undergoing mammography alone. The researchers also could not evaluate the cost-effectiveness and the effect of MRI or ultrasonography screening on survival benefit.
Source: JAMA Oncology
Image Credit: Pixabay
Published on : Tue, 27 Jun 2017
Print as PDF
We recognize that the best chance any patient has at getting better is a clinician at their bedside with all the right answers and the confidence to act. SonoSite education and training is the industry standard – no other point-of-care ultrasound manufacturer...
The iViz is a lightweight Point Of Care (POC) ultrasound solution, specifically designed for emerging sub-segments where there is need for a highly accessible and mobile solution that is capable throughout key areas of the patient care path. The iViz...
For users who value state-of-the art technology: Power and flexibility of a PC in a portable ECG Bidirectional Wi-Fi communication Culprit Coronary Artery AlgorithmTM for early STEMI detection The CARDIOVIT FT-1 is ultra-portable:...
The new 3Dimensions™ Mammography System matches the unrivaled performance of our 3D Mammography™ exam, which is more accurate than conventional 2D mammograms, detecting 20-65% more invasive breast cancers.Breakthrough improvements transform the patient...
Powered by the most revolutionary ZONE Sonography® Technology, Resona 7’s new ZST+ platform brings the ultrasound image quality to a higher level by zone acquisition and channel data processing. Resona 7 also provides clinical research with the revolutionary...